Spyglass Pharma (NASDAQ:SGP) Stock Falls 7.2% – Should You Sell?

Posted by Stanley Muller on Nov 10th, 2026

Spyglass Pharma, Inc. (NASDAQ:SGP – Get Free Report) shares traded down 7.2% during mid-day trading on Tuesday. The company traded as low as $36.71 and last traded at $35.6090. Approximately 14,119 shares were traded during mid-day trading, a decline of 87% from the average session volume of 108,943 shares. The stock had previously closed at $38.37.

Wall Street Analysts Forecast Growth

Several equities analysts have commented on the company. HC Wainwright reiterated a “buy” rating and issued a $37.00 target price on shares of Spyglass Pharma in a research report on Wednesday, October 21st. Raymond James Financial started coverage on Spyglass Pharma in a research note on Friday, August 14th. They issued an “outperform” rating and a $39.00 price objective for the company. Weiss Ratings downgraded Spyglass Pharma from a “sell (e+)” rating to a “sell (e)” rating in a research note on Friday, September 25th. UBS Group reiterated a “buy” rating on shares of Spyglass Pharma in a report on Monday, October 5th. Finally, Wall Street Zen upgraded shares of Spyglass Pharma from a “sell” rating to a “hold” rating in a research report on Saturday, October 31st. Seven research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Spyglass Pharma currently has a consensus rating of “Moderate Buy” and a consensus price target of $44.00.

Get Our Latest Analysis on Spyglass Pharma

Spyglass Pharma Trading Down 8.0%

The firm has a market capitalization of $1.18 billion and a P/E ratio of -5.04. The company has a 50-day moving average of $28.28 and a 200-day moving average of $24.63.

Hedge Funds Weigh In On Spyglass Pharma

A number of hedge funds and other institutional investors have recently made changes to their positions in SGP. First Light Asset Management LLC bought a new stake in Spyglass Pharma in the first quarter valued at approximately $9,716,000. Affinity Asset Advisors LLC acquired a new stake in Spyglass Pharma during the 1st quarter valued at approximately $6,478,000. Monashee Investment Management LLC bought a new position in Spyglass Pharma during the 1st quarter worth approximately $2,461,000. Bank of America Corp DE bought a new position in Spyglass Pharma during the 1st quarter worth approximately $726,000. Finally, Bank of New York Mellon Corp acquired a new position in shares of Spyglass Pharma in the 2nd quarter worth approximately $533,000.

About Spyglass Pharma

(Get Free Report)

SpyGlass Pharma is a clinical-stage ophthalmology company developing sustained-release drug delivery systems for chronic eye diseases. Its research is focused on reducing reliance on patients’ regular use of eye drops. The company’s lead program is a bimatoprost drug delivery system being developed to treat glaucoma and ocular hypertension. Bimatoprost is a medication used to lower eye pressure, and SpyGlass is studying a delivery approach intended to provide treatment over an extended period. SpyGlass Pharma’s work centers on advancing this ophthalmic delivery platform and its lead program through clinical development.